Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells

@inproceedings{Fiskus2015PreclinicalEO,
  title={Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells},
  author={Warren Fiskus and Sunil Datt Sharma and Saikat Saha and Bhavin Shah and Santhana G. T. Devaraj and Baohua Sun and Stephen K Horrigan and Christopher Leveque and Youli Zu and Swaminathan Padmanabhan Iyer and Kapil N. Bhalla},
  booktitle={Leukemia},
  year={2015}
}
The canonical wingless-type MMTV integration site (WNT)-β-catenin pathway is essential for self-renewal, growth and survival of acute myeloid leukemia (AML) stem/blast progenitor cells (BPCs). Deregulated WNT signaling inhibits degradation of β-catenin, causing increased nuclear translocation and co-factor activity of β-catenin with the transcriptional regulator T-cell factor (TCF) 4/lymphoid enhancer factor 1 in AML BPCs. Here, we determined the pre-clinical anti-AML activity of the… CONTINUE READING